| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Crescent Biopharma, Inc. (CBIO) has 9 insiders with recent SEC Form 4 filings, including 12 buys and 7 sells. CBIO is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 3.60M | $56.79M | +1.38M | |
| CEO | 180.5K | $2.85M | - | |
| COO | 78.0K | $1.23M | - | |
| Other | 54.2K | $854.6K | - | |
| Other | 17.5K | $276.1K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 16, 2021 | Andrews Patricia S | Director | Buy | 40,000 | $2.05 | $82,000.00 | +761.9% | -48.0% | -7.0% | |
| Dec 28, 2020 | King Rachel K. | President, CEO | Sale+OE | 84,176 | $3.91 | $329,128.16 | -19.1% | - | - | |
| Nov 4, 2020 | Bvf Partners L P/il60 | 10% Owner | Buy | 1,266,737 | $2.60 | $3,293,516.20 | +15.7% | - | - | |
| Oct 30, 2020 | Bvf Partners L P/il60 | 10% Owner | Buy | 932,612 | $2.75 | $2,564,683.00 | +13.1% | - | - | |
| Mar 9, 2020 | Junius Daniel M | Director | Buy | 20,000 | $3.40 | $68,000.00 | +111.1% | - | - | |
| Sep 5, 2019 | Bvf Partners L P/il60 | 10% Owner | Buy | 1,668,746 | $3.18 | $5,309,949.77 | +30.6% | - | - | |
| Aug 13, 2019 | Junius Daniel M | Director | Buy | 10,000 | $3.18 | $31,800.00 | +125.0% | - | - | |
| Oct 18, 2018 | Magnani John L. | SVP Of Research, CSO | Sell | 25,000 | $14.01 | $350,212.54 | -9.4% | - | - | |
| Jun 11, 2018 | Hahn Brian M.47 | CFO | Sale+OE | 19,345 | $18.04 | $348,983.80 | -100% | - | - | |
| May 10, 2018 | Sandell Scott D55 | 10% Owner | Sell | 9,539 | $17.81 | $169,889.59 | - | - | - |